A5007136335- Occupational and environmental lung diseases
- Lung Cancer Research Studies
- Pleural and Pulmonary Diseases
- Cancer Immunotherapy and Biomarkers
- Medical Imaging and Pathology Studies
- Peptidase Inhibition and Analysis
- Cytokine Signaling Pathways and Interactions
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Lung Cancer Treatments and Mutations
- Immune cells in cancer
- Cell Adhesion Molecules Research
- Glycosylation and Glycoproteins Research
- Neuroendocrine Tumor Research Advances
- Cancer Research and Treatments
- Monoclonal and Polyclonal Antibodies Research
- Medical Imaging Techniques and Applications
- Ferroptosis and cancer prognosis
- Radiation Dose and Imaging
- Neuroblastoma Research and Treatments
- MicroRNA in disease regulation
- Pancreatic and Hepatic Oncology Research
- Epigenetics and DNA Methylation
- RNA modifications and cancer
- Drug Transport and Resistance Mechanisms
- Endometriosis Research and Treatment
Hyogo University
2023-2025
Hyogo Medical University
2017-2024
Kyoto Prefectural University of Medicine
2023
Keio University
2021
Juntendo University
2021
Nihon University
2021
Kitasato University
2021
University of California, San Diego
2017-2019
Sanford Consortium for Regenerative Medicine
2017-2019
Hyogo Prefectural Nishinomiya Hospital
2019
Abstract Introduction Nivolumab plus ipilimumab with chemotherapy (NICT) and pembrolizumab (PCT) are commonly used in patients advanced non-small cell lung cancer (NSCLC). Compared immune checkpoint inhibitor (ICI) monotherapy, ICI combination therapy can increase immune-related toxicity instead of prolonging survival. This study aimed to compare the efficacy safety NICT PCT decide on favorable treatment. Methods We conducted a multi-center retrospective cohort who underwent or between...
Abstract Small cell lung cancer (SCLC) is an aggressive malignancy with extremely high mortality due to the appearance of widespread metastases early in its clinical course and rapid acquisition chemoresistance after initial therapy. A theory adhesion–mediated drug resistance thought be a principal mechanism which extracellular matrix proteins provide survival advantage against cytotoxic drug-induced apoptosis. We found that tetraspanin family member CD9 was expressed preferentially SCLC...
Abstract Stat3 mediates a complex spectrum of cellular responses, including inflammation, cell proliferation, and apoptosis. Although evidence exists in support positive role for cancer, its has remained somewhat controversial because insufficient study how genetic deletion may affect carcinogenesis various tissues. In this study, we show using epithelium-specific knockout mice (Stat3Δ/Δ) that blunts rather than supports antitumor immunity carcinogen-induced lung tumorigenesis. Stat3Δ/Δ did...
Idiopathic pulmonary fibrosis (IPF) is a chronic disorder of unknown etiology with few treatment options. Although tetraspanins are involved in various diseases, their roles have not been determined.To investigate the role tetraspanin CD151 fibrosis.CD151 knockout (KO) mice were studied by histological, biochemical, and physiological analyses compared wild-type CD9 KO mice. Further mechanistic performed vitro, vivo, on samples from patients IPF.A microarray study identified an enrichment...
Tetraspanins organize protein complexes in tetraspanin-enriched membrane microdomains that are distinct from lipid rafts. Our previous studies suggested reduction the levels of tetraspanins CD9 and CD81 may be involved progression inflammatory lung diseases, especially COPD. To search for agents increase these tetraspanins, we screened 1,165 drugs clinical use found statins upregulate RAW264.7 macrophages. The lipophilic statins, fluvastatin simvastatin, reversed LPS-induced downregulation...
Although responses to EGFR tyrosine kinase inhibitors (EGFR-TKIs) are initially positive, 30%-40% of patients with EGFR-mutant tumors do not respond well EGFR-TKIs, and most lung cancer harboring mutations experience relapse resistance. Therefore, it is necessary identify only the mechanisms underlying EGFR-TKI resistance, but also potentially novel therapeutic targets and/or predictive biomarkers for adenocarcinoma. We found that GPI-anchored protein semaphorin 7A (SEMA7A) highly induced by...
ABSTRACT Steroid‐refractory immune‐related pneumonitis is a clinical challenge with limited evidence‐based treatment strategies. Current guidelines recommend the use of immunosuppressants; however, optimal type and dosage these agents remain unclear. Herein, we report case steroid‐refractory that was successfully treated mycophenolate mofetil (MMF). The patient did not respond to high‐dose steroid therapy as initial but showed significant improvement in both subjective symptoms imaging...
Introduction: In August 2018, the Japanese PMDA approved nivolumab, an immune checkpoint inhibitor (ICI), for previously treated, unresectable, advanced, or recurrent pleural mesothelioma (PM) based on MERIT trial, a phase II study of 34 cases. However, concerns regarding limited evidence persist. Methods: We retrospectively analyzed 83 patients with malignant (MPM) treated nivolumab from 2018 to May 2022. Efficacy was evaluated using overall response rate (ORR), progression-free survival...
ABSTRACT Background Bone metastasis (BoM) is common in advanced cancer, but its incidence pleural mesothelioma (PM) remains unclear. This study aimed to determine the of BoM PM patients and assess prognosis risk factors clarify clinical significance. Methods A retrospective analysis was conducted on 515 histologically confirmed enrolled between January 2011 December 2020. The cumulative calculated using Kaplan–Meier method, with group differences assessed via log‐rank tests. Risk for were...
Abstract Tumor-associated macrophages (TAM) are highly expressed within the tumor microenvironment of a wide range cancers, where they exert protumor phenotype by promoting cell growth and suppressing antitumor immune function. Here, we show that TAM accumulation in human mouse tumors correlates with expression integrin αvβ3, known driver epithelial cancer progression drug resistance. A monoclonal antibody targeting αvβ3 (LM609) exploited coenrichment TAMs to not only eradicate aggressive...
CXCL12 is a chemokine essential for the organ‐specific spread of variety cancers including small cell lung cancer (SCLC). Here, we examined anti‐metastatic efficacy TF14016, peptidic inhibitor receptor CXCR4, in SCLC. Treatment mice with TF14016 significantly suppressed pulmonary metastases CXCR4‐expressing SCLC size and number. Furthermore, histological examination revealed that expression vascular endothelial growth factor density CD31‐positive microvessels metastatic foci were both...
Abstract Small-cell lung cancer (SCLC) easily recurs with a multidrug resistant phenotype. However, standard therapeutic strategies for relapsed SCLC remain unestablished. We found that human epidermal growth factor receptor 2 (HER2) is not only expressed in pretreated specimens, but also upregulated when HER2-positive cells acquire chemoresistance. Trastuzumab induced differential levels of antibody-dependent cell-mediated cytotoxicity (ADCC) to cells. Furthermore, as mechanism the ADCC, we...
Small cell lung cancer (SCLC) easily acquires multidrug resistance after successful initial therapy. Overexpression of ATP-binding cassette (ABC) transporters is important for the resistance. Among them, ABCB1 and ABCG2 are known to be upregulated in chemoresistant SCLC cells. We found that human epidermal growth factor receptor 2 (HER2) expressions also SBC-3/ETP, SBC-3/SN-38, SBC-3/CDDP cells, compared with chemosensitive SBC-3 Lapatinib, a tyrosine kinase inhibitor HER2, could not...
Abstract Malignant pleural mesothelioma (MPM) is an asbestos‐related aggressive malignant neoplasm. Due to the difficulty of achieving curative surgical resection in most patients with MPM, a combination chemotherapy cisplatin and pemetrexed has been only approved regimen proven improve prognosis MPM. However, median overall survival time at 12 mo even this regimen. There therefore pressing need develop novel chemotherapeutic strategy bring about better outcome for We found that expression...
Abstract We present a patient with lung adenocarcinoma showing high PD‐L1 expression and BRAF V600E mutation, who achieved remarkable long‐term response to the combination therapy of dabrafenib trametinib (DT treatment) after disease progression on immunotherapy. This case may provide an opportunity for clinicians consider order administration immunotherapy molecular targeted V600E‐positive cancer.
Abstract Chronic fibrosing idiopathic interstitial pneumonia (IIP) can be divided into two main types: pulmonary fibrosis (IPF), a steroid-resistant and progressive disease with median survival of 2–3 years, non-specific (INSIP), steroid-sensitive non-progressive autoimmune disease. Although the clinical courses these diseases differ, they may difficult to distinguish at diagnosis. We performed comprehensive analysis serum autoantibodies from patients definitively diagnosed IPF, INSIP,...